Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Cymeed who wrote (422)	12/13/1997 10:43:00 AM
From: Peter Silsbee	Read Replies (1) \| Respond to of 887

[RE: GLIA] To set the record straight, the stock tanked BEFORE the recommendation for approval. Apparently because, at the panel, "some tough questions were being asked." (What did people think these panels were about, anyway?) Trading was halted for well over an hour before any announcement about the committee's decision was made, and the stock did NOT trade after the announcement. PLS

To: Cymeed who wrote (422)	12/13/1997 11:30:00 AM
From: John McCarthy	Read Replies (1) \| Respond to of 887

Cymeed - <<I would not be totally surprised to see Depo tanks too on Dec 19. This all depends on the thinking of the crowd, which is totally unpredicatable.>> If you bought into DEPO for the bounce, I would be afraid. If South Korea tanks next week, i.e. the WON goes to a billion for the dollar, all stocks w/o earnings will get slammed. And those with earnings - will get slammed. No one will care about earnings prospects. Things will be in chaos until new safe market sectors are defined. High tech and biotech ain't gonna cut it, at least initially. That out of the way, there is no connection between GLIA and DEPO. Or DEPO and any other drug up for review. DEPO delivers a chemo drug in a very efficient manner which (a) lets someone live a little bit longer than otherwise - yes - they STILL die using DC (b) or, potentially, DEPO (DC) saves someones life who otherwise would have died because DC was introduced early in the program. As doctors climbed the learning curve, they will reach for the bottle sooner, both on and off-label. They want to win - they want their patient to win. DEPO gives them a chance for winning. This is why the prospect for DEPO is so large. Look at it this way, people are already dead who should not be, because this drug is not freely available. But none of these assumptions, on may part, will be reflected in the price of DEPO until we are near the FINAL, FINAL, SUPER FINAL FDA review. Whenever that is. Regards, John McCarthy